作者: Teresa Troiani , Stefania Napolitano , Carminia Maria Della Corte , Giulia Martini , Erika Martinelli
DOI: 10.1136/ESMOOPEN-2016-000088
关键词:
摘要: Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, is one of the most important targets for biological therapy, especially non-small-cell lung cancer (NSCLC) colorectal (CRC). In past 15 years, several EGFR antagonists have been approved treatment NSCLC metastatic CRC (mCRC). To optimise use anti-EGFR agents clinical practice, various molecular biomarkers investigated, thus moving their indication from unselected to selected populations. Nowadays, drugs represent gold-standard therapy harbouring activating mutation RAS wild-type mCRC. Their efficacy limited by presence intrinsic resistance or onset acquired resistance. this review, we provide an overview antitumour activity inhibitors mechanisms resistance, focusing on development personalised approach through 15 years preclinical research.